|Expense Ratio (net)||0.74%|
|Morningstar Risk Rating||★★★★★|
|Last Cap Gain||0.00|
|Inception Date||Dec 16, 1985|
|Average for Category||N/A|
Biotech stocks have taken off since President Trump took office. Through the end of July, the iShares Biotech ETF is up almost 19%, well ahead of broader market benchmarks. If you are thinking of investing in biotech stocks after this rally, here's what you need to know.
Removal of healthcare restrictions and biotech gains make mutual funds from this sector a strong investment choice.
Fidelity Select Biotechnology Portfolio (FBIOX) seeks capital appreciation